LIR Life Sciences Corp. is a Canada-based company. The Company is engaged in developing therapies across multiple treatment areas, with a focus on obesity and metabolic disorders. It develops glucagon-like peptide-1 (GLP-1) based therapies for patients. It has access to a drug delivery system and plans to utilize technology to enable the needle-free administration of complex large-molecule biologics which provides a potential alternative to injectable treatments across a wide variety of treatments and diseases. The Company develops LIR001 Dual-Action Therapy (LIR001). LIR001 combines GLP-1 receptor agonists with other drugs to enhance obesity treatment by targeting both metabolic and behavioral factors. GLP-1 receptor agonists, such as liraglutide and semaglutide, regulate blood sugar, promote insulin release, and slow gastric emptying, leading to reduced appetite and improved insulin sensitivity.